Insider · CIK 0001260573

KARSEN PERRY A

Reports to the SEC for 13 companies · SUMMIT, NJ

sec.gov

Transactions

Companies

Filings

CIK

0001260573

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2023-07-19	LENZLENZ Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+20K sh	—	—	20,000
2023-05-03	Jounce Therapeutics, Inc.U Disposition from Tender	Director	UDisposition from Tender	−5,000 sh	—	—	0
2023-05-03	Jounce Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−15.7K sh	—	—	0
2023-05-03	Jounce Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−13.4K sh	—	—	0
2023-05-03	Jounce Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−15.7K sh	—	—	0
2023-05-03	Jounce Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−20K sh	—	—	0
2023-05-03	Jounce Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−75.9K sh	—	—	0
2023-05-03	Jounce Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−15.7K sh	—	—	0
2023-05-03	Jounce Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−16.3K sh	—	—	0
2022-06-24	Jounce Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+20K sh	—	—	20,000
2022-06-21	LENZLENZ Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+20K sh	—	—	20,000
2021-06-29	LENZLENZ Therapeutics, Inc.C Conversion	Director	CConversion	+8,126 sh	—	—	164,034
2021-06-29	LENZLENZ Therapeutics, Inc. · Series B Preferred StockC Conversion	Director	CConversion	−19.8K sh	—	—	0
2021-06-18	Jounce Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+15.7K sh	—	—	15,700
2021-03-17	LENZLENZ Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+18.7K sh	—	—	18,698
2021-03-11	LENZLENZ Therapeutics, Inc. · Series B Preferred StockA Award	Director	AAward	+19.8K sh	$5.06	+$100K	19,763
2021-01-13	LENZLENZ Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+74.8K sh	—	—	74,794
2020-12-17	NTLAIntellia Therapeutics, Inc.S Sale	Director	SSale	−45.5K sh	$53.69	−$2.44M	26,336
2020-12-17	NTLAIntellia Therapeutics, Inc.S Sale	Director	SSale	−22K sh	$52.52	−$1.15M	71,786
2020-12-17	NTLAIntellia Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+19K sh	$15.78	+$300K	93,764
2020-12-17	NTLAIntellia Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+19K sh	$25.98	+$494K	74,764
2020-12-17	NTLAIntellia Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+19K sh	$14.35	+$273K	55,764
2020-12-17	NTLAIntellia Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+31.8K sh	$18.00	+$572K	36,764
2020-12-17	NTLAIntellia Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−19K sh	—	—	0
2020-12-17	NTLAIntellia Therapeutics, Inc.S Sale	Director	SSale	−21.3K sh	$54.33	−$1.16M	5,000
2020-12-17	NTLAIntellia Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−19K sh	—	—	0
2020-12-17	NTLAIntellia Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−19K sh	—	—	0
2020-12-17	NTLAIntellia Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−31.8K sh	—	—	0
2020-06-26	Jounce Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+15.7K sh	—	—	15,700
2020-06-26	Jounce Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+13.6K sh	—	—	13,550
2020-06-18	NTLAIntellia Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+19K sh	—	—	19,000
2019-06-13	VYGRVoyager Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+15K sh	—	—	15,000
2019-06-12	Jounce Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+15.7K sh	—	—	15,700
2019-05-21	NTLAIntellia Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+19K sh	—	—	19,000
2019-04-23	OncoMed Pharmaceuticals IncU Disposition from Tender	Director	UDisposition from Tender	−80.5K sh	—	—	0
2018-06-22	OncoMed Pharmaceuticals IncStock Option (Right to Buy)A Award	Director	AAward	+15K sh	—	—	15,000
2018-06-19	Jounce Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+13.6K sh	—	—	13,550
2018-06-14	VYGRVoyager Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+15K sh	—	—	15,000
2018-05-17	NTLAIntellia Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+19K sh	—	—	19,000
2018-02-26	OncoMed Pharmaceuticals IncStock Option (Right to Buy)A Award	Director	AAward	+120K sh	—	—	120,000
2018-02-26	OncoMed Pharmaceuticals IncA Award	Director	AAward	+70.5K sh	—	—	80,500
2017-06-29	VYGRVoyager Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+15K sh	—	—	15,000
2017-06-05	OncoMed Pharmaceuticals IncP Purchase	Director	PPurchase	+10K sh	$3.46	+$34.6K	10,000
2017-06-01	NTLAIntellia Therapeutics, Inc.A Award	Director	AAward	+5,000 sh	$11.98	+$59.9K	5,000
2017-06-01	OncoMed Pharmaceuticals IncStock Option (Right to Buy)A Award	Director	AAward	+15K sh	—	—	15,000
2017-05-18	NTLAIntellia Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+19K sh	—	—	19,000
2017-02-01	Jounce Therapeutics, Inc.P Purchase	Director	PPurchase	+5,000 sh	$16.00	+$80K	5,000
2016-06-22	OncoMed Pharmaceuticals IncStock Option (Right to Buy)A Award	Director	AAward	+15K sh	—	—	15,000
2016-06-15	VYGRVoyager Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+15K sh	—	—	15,000
2016-05-05	NTLAIntellia Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+31.8K sh	—	—	31,764

Recent filings

Accepted (ET)
Jul 214
KARSEN PERRY A0001209191-23-043140
SEC(opens sec.gov)
May 44
KARSEN PERRY A0001640455-23-000111
SEC(opens sec.gov)
Jun 284
KARSEN PERRY A0001640455-22-000073
SEC(opens sec.gov)
Jun 224
KARSEN PERRY A0001209191-22-038734
SEC(opens sec.gov)
Jul 14
KARSEN PERRY A0000899243-21-027012
SEC(opens sec.gov)
Jun 224
KARSEN PERRY A0001640455-21-000108
SEC(opens sec.gov)
Dec 184
KARSEN PERRY A0001209191-20-064425
SEC(opens sec.gov)

Companies

Address

C/O STALAR 4, INC. 86 MORRIS AVENUE

SUMMIT, NJ, 07901